Hypothesis of using albumin to improve drug efficacy in cancers accompanied by hypoalbuminemia

References

• Alfarouk KO, Stock C-M, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AHH, Mohammed OY, Elhassan GO, Harguindey S, et al. 2015. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 15(1):71.
   PubMed Web of Science ®Google Scholar
• Almasaudi AS, Dolan RD, Edwards CA, McMillan DC. 2020. Hypoalbuminemia reflects nutritional risk, body composition and systemic inflammation and is independently associated with survival in patients with colorectal cancer. Cancers (Basel). 12(7):1986.
   PubMed Web of Science ®Google Scholar
• Bagheri S. 2019. The effect of arsenic trioxide on all-trans retinoic acid binding to human serum albumin. J Fluoresc. 29(6):1277–1283.
   PubMed Web of Science ®Google Scholar
• Bekos C, Polterauer S, Seebacher V, Bartl T, Joura E, Reinthaller A, Sturdza A, Horvat R, Schwameis R, Grimm C, et al. 2019. Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery. Arch Gynecol Obstet. 300(4):1015–1022.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Zia-Amirhosseini P. 1995. Basic principles of pharmacokinetics. Toxicol Pathol. 23(2):115–123.
   PubMed Web of Science ®Google Scholar
• Bohnert T, Gan LS. 2013. Plasma protein binding: From discovery to development. J Pharm Sci. 102(9):2953–2994.
   PubMed Web of Science ®Google Scholar
• Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. 2009. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents. 33(5):432–436.
   PubMed Web of Science ®Google Scholar
• Bukowski K, Kciuk M, Kontek R. 2020. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 21(9):3233.
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, Welte T. 2006. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: Pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother. 59(2):277–284.
   PubMed Web of Science ®Google Scholar
• Caira MR, Ionescu C. 2005. Drug Metabolism: Current Concepts. Netherlands: Springer.
   Google Scholar
• Campbell PM, Der CJ. 2004. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol. 14(2):105–114.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, et al. 2018. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Ann Hematol. 97(10):1797–1802.
   PubMed Web of Science ®Google Scholar
• Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, et al. 2013. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 497(7451):633–637.
   PubMed Web of Science ®Google Scholar
• Conner BJ. 2017. Treating hypoalbuminemia. Vet Clin North Am – Small Anim Pract. 47(2):451–459.
   PubMed Web of Science ®Google Scholar
• Conrad LB, Awdeh H, Acosta-Torres S, Conrad SA, Bailey AA, Miller DS, Lea JS. 2018. Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. J Surg Oncol. 117(5):1020–1028.
   PubMed Web of Science ®Google Scholar
• de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, et al. 2008. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 111(7):3395–3402.
   PubMed Web of Science ®Google Scholar
• Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA. 2002. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Bio Chem. 277(38):35035–35043.
   PubMed Web of Science ®Google Scholar
• Derakhshankhah H, Izadi Z, Alaei L, Lotfabadi A, Saboury AA, Dinarvand R, et al. 2017. Colon cancer and specific ways to deliver drugs to the large intestine. Anticancer Agents Med Chem. 17:1317–1327.
   PubMed Web of Science ®Google Scholar
• Farasatinasab M, Amouzegar A, Safari S, Ghanbari B, Darkahian M, Emami S, Pakdaman N, Salili M. 2018. Albumin utilization evaluation in a major teaching hospital in Iran: recommendations for guideline development. J Res Pharm Pract. 7(3):157–163.
   PubMed Web of Science ®Google Scholar
• Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P. 2005. The extraordinary ligand binding properties of human serum albumin. IUBMB Life. 57(12):787–796.
   PubMed Web of Science ®Google Scholar
• Franch-Arcas G. 2001. The meaning of hypoalbuminaemia in clinical practice. Clin. Nutr. 20(3):265–269.
   PubMed Web of Science ®Google Scholar
• Fritzsche T, Schnölzer M, Fiedler S, Weigand M, Wiessler M, Frei E. 2004. Isolation and identification of heterogeneous nuclear ribonucleoproteins (hnRNP) from purified plasma membranes of human tumour cell lines as albumin-binding proteins. Biochem Pharmacol. 67(4):655–665.
   PubMed Web of Science ®Google Scholar
• Gatta A, Verardo A, Bolognesi M. 2012. Hypoalbuminemia. Intern Emerg Med. 7(S3):193–S199.
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Koup JR. 1981. Pharmacokinetic concepts – drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol. 20(4):299–305.
   PubMed Web of Science ®Google Scholar
• Greish K, Nagamitsu A, Fang J, Maeda H. 2005. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjugate Chem. 16(1):230–236.
   PubMed Web of Science ®Google Scholar
• Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, et al. 1999. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Clin Cancer Res. 5:753–759.
   PubMed Web of Science ®Google Scholar
• Haskins IN, Baginsky M, Amdur RL, Agarwal S. 2017. Preoperative hypoalbuminemia is associated with worse outcomes in colon cancer patients. Clin Nutr. 36(5):1333–1338.
   PubMed Web of Science ®Google Scholar
• Hauser CA, Stockler MR, Tattersall MHN. 2006. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer. 14(10):999–1011.
   PubMed Web of Science ®Google Scholar
• Hijazi Y. 2021. Prediction of half-life extension of peptides via serum albumin binding: current challenges. Eur J Drug Metab Pharmacokinet. 46(2):163–172.
   PubMed Web of Science ®Google Scholar
• Hu T, Li Z, Gao CY, Cho CH. 2016. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 22(30):6876–6889.
   PubMed Web of Science ®Google Scholar
• Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, et al. 2015. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 75(3):544–553.
   PubMed Web of Science ®Google Scholar
• Kim TY, Park JH, Shim HE, Choi DS, Lee D-E, Song J-J, Kim H-S. 2019. Prolonged half-life of small-sized therapeutic protein using serum albumin-specific protein binder. J Control Release. 315:31–39.
   PubMed Web of Science ®Google Scholar
• Kok-Yong S, Lawrence L. 2015. Chapter 4: drug distribution and drug elimination. In: Ahmed TA , editor. Basic pharmacokinetic concepts and some clinical applications. London, UK: InTech.
   Google Scholar
• Kratz F. 2008. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release. 132(3):171–183.
   PubMed Web of Science ®Google Scholar
• Kremer P, Mahmoudreza F, Ding R, Pritsch M, Zoubaa S, Frei E. 2009. Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery. 64(3 Suppl):ons53–60.
   PubMed Web of Science ®Google Scholar
• Larsen MT, Kuhlmann M, Hvam ML, Howard KA. 2016. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. 4:1–12.
   PubMedGoogle Scholar
• Lee J-I, Kwon M, Roh J-L, Choi JW, Choi S-H, Nam SY, Kim SY. 2015. Postoperative hypoalbuminemia as a risk factor for surgical site infection after oral cancer surgery. Oral Dis. 21(2):178–184.
   PubMed Web of Science ®Google Scholar
• Levitt DG, Levitt MD. 2016. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. Volume 9:229–255.
   Web of Science ®Google Scholar
• Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, Wang X, Lyu Y, Chen X, Liu K, et al. 2019. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B. 9(6):1113–1144.
   PubMed Web of Science ®Google Scholar
• Lin S‐R, Chang C‐H, Hsu C‐F, Tsai M‐J, Cheng H, Leong MK, Sung P‐J, Chen J‐C, Weng C‐F. 2020. Natural compounds as potential adjuvants to cancer therapy: preclinical evidence. Br J Pharmacol. 177(6):1409–1423.
   PubMed Web of Science ®Google Scholar
• Lindenmann J, Fink-Neuboeck N, Koesslbacher M, Pichler M, Stojakovic T, Roller RE, Maier A, Anegg U, Smolle J, Smolle-Juettner FM, et al. 2014. The influence of elevated levels of C-reactive protein and hypoalbuminemia on survival in patients with advanced inoperable esophageal cancer undergoing palliative treatment. J Surg Oncol. 110(6):645–650.
   PubMed Web of Science ®Google Scholar
• Mahmoodpoor A, Zahedi S, Pourakbar A, Hamishehkar H, Shadvar K, Asgharian P, Shahabi F, Hamishehkar H. 2020. Efficacy of furosemide-albumin compared with furosemide in critically ill hypoalbuminemia patients admitted to intensive care unit: a prospective randomized clinical trial. DARU J Pharm Sci. 28(1):263–269.
   Web of Science ®Google Scholar
• Mansoor A, Mahabadi N. 2020. Volume of Distribution. Treasure Island (FL): StarPearls Publishing.
   Google Scholar
• Mayr J, Heffeter P, Groza D, Galvez L, Koellensperger G, Roller A, Alte B, Haider M, Berger W, Kowol CR, et al. 2017. An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. Chem Sci. 8(3):2241–2250.
   PubMed Web of Science ®Google Scholar
• Melia D, Post B. 2020. Human albumin solutions in intensive care: a review. J Intensive Care Soc. DOI:10.1177/1751143720961245
   PubMedGoogle Scholar
• Merlot AM, Kalinowski DS, Richardson DR. 2014. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol. 5:299.
   PubMed Web of Science ®Google Scholar
• Merlot AM, Pantarat N, Menezes SV, Sahni S, Richardson DR, Kalinowski DS. 2013. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanisms. Mol Pharmacol. 84(6):911–924.
   PubMed Web of Science ®Google Scholar
• Merlot AM, Richardson DR. 2014. Receptor Recognition and Lysosomal Targeting to Enhance Cytotoxicity of Novel Anti-Cancer Agents that Bind Iron and Copper. Vitam Miner. 3(1):1000e125.
   Google Scholar
• Mimoz O, Phan Soreda S, Padoin C, Tod M, Petitjean O, Benhamou D. 2000. Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia A model to explore the effects of decreased protein binding capacity on highly bound drugs. Anesthesiology. 93(3):735–778.
   PubMed Web of Science ®Google Scholar
• Mohr JF, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD. 2008. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. AAC. 52(5):1891–1893.
   Web of Science ®Google Scholar
• Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, on behalf of the PETHEMA and HOVON Groups, et al. 2011. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 117(6):1799–1805.
   PubMed Web of Science ®Google Scholar
• Moujaess E, Fakhoury M, Assi T, Elias H, El Karak F, Ghosn M, Kattan J. 2017. The therapeutic use of human albumin in cancer patients’ management. Crit Rev Oncol Hematol. 120:203–209.
   PubMed Web of Science ®Google Scholar
• Muindi JR, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, et al. 1992. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 52:2138–2142.
   PubMed Web of Science ®Google Scholar
• Ñamendys-Silva SA, González-Herrera MO, Texcocano-Becerra J, Herrera-Gómez A. 2011. Hypoalbuminemia in critically ill patients with cancer: incidence and mortality. Am J Hosp Palliat Care. 28(4):253–257.
   PubMed Web of Science ®Google Scholar
• Nazha B, Moussaly E, Zaarour M, Weerasinghe C, Azab B. 2015. Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 7(12):370–377.
   PubMed Web of Science ®Google Scholar
• Øie S. 1986. Drug distribution and binding. J Clin Pharmacol. 26(8):583–586.
   PubMed Web of Science ®Google Scholar
• Palavalli Parsons LH, Roane B, Manders DB, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS. 2018. Hypoalbuminemia is a predictive factor for fistula formation in recurrent cervical cancer. Am J Clin Oncol Cancer Clin Trials. 41(10):933–937.
   PubMed Web of Science ®Google Scholar
• Patatanian E, Thompson DF. 2008. Retinoic acid syndrome: a review. J Clin Pharm Ther. 33(4):331–338.
   PubMed Web of Science ®Google Scholar
• Paul A. 2019. Drug distribution. In: Marshall Raj GD, Raveendran R, editors. Introduction to basics of pharmacology and toxicology: volume 1: general and molecular pharmacology: principles of drug action. Singapore: Springer. p. 89–98.
   Google Scholar
• Peters TJ. 1996. Chapter 5: metabolism: albumin in the body. All about albumin. Biochemistry, Genetics and Medical Applications. San Diego: Academic Press
   Google Scholar
• Pilati D, Howard KA. 2020. Albumin-based drug designs for pharmacokinetic modulation. Expert Opin Drug Metab Toxicol. 16(9):783–795.
   PubMed Web of Science ®Google Scholar
• Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. 2019. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 11:1–19.
   Google Scholar
• Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. 2019. The neonatal Fc Receptor (FcRn): a misnomer?Front Immunol. 10:1540.
   PubMed Web of Science ®Google Scholar
• Ramadori G, Cameron S. 2010. Effects of systemic chemotherapy on the liver. Ann. Hepatol. 9(2):133–143.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Pea F, Lipman J. 2013. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 52(1):1–8.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Gonzalez D, Derendorf H. 2010. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci. 99(3):1107–1122.
   PubMed Web of Science ®Google Scholar
• Shen Z-X, Chen G-Q, Ni J-H, Li X-S, Xiong S-M, Qiu Q-Y, Zhu J, Tang W, Sun G-L, Yang K-Q, et al. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (AFL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89(9):3354–3360.
   PubMed Web of Science ®Google Scholar
• Shi WJ, Gao JB. 2016. Molecular mechanisms of chemoresistance in gastric cancer. World J Gastroenterol Oncol. 8(9):673–681.
   PubMed Web of Science ®Google Scholar
• Sleep D. 2015. Albumin and its application in drug delivery. Expert Opin Drug Deliv. 12(5):793–812.
   PubMed Web of Science ®Google Scholar
• Sleep D, Cameron J, Evans LR. 2013. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta – Gen Subj. 1830(12):5526–5534.
   PubMed Web of Science ®Google Scholar
• Stehle G, Sinn H, Wunder A, Schrenk HH, Schütt S, Maier-Borst W, et al. 1997a. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs. 8:677–685.
   PubMed Web of Science ®Google Scholar
• Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JCM, Hartung G, Maier-Borst W, Heene DL. 1997b. Plasma protein (albumin) catabolism by the tumor itself – Implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 26(2):77–100.
   PubMed Web of Science ®Google Scholar
• Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M, Komoda M, Kono M, Fukata M, Arita T, et al. 2019. Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. Gastric Cancer. 22(5):988–998.
   PubMed Web of Science ®Google Scholar
• Takitani K, Tamai H, Morinobu T, Kawamura N, Miyake M, Fujimoto T, Mino M. 1995. Pharmacokinetics of all-trans retinoic acid in pediatric patients with leukemia. Japanese J Cancer Res. 86(4):400–405.
   PubMedGoogle Scholar
• Tanzadehpanah H, Mahaki H, Moradi M, Afshar S, Rajabi O, Najafi R, Amini R, Saidijam M. 2018. Human serum albumin binding and synergistic effects of gefitinib in combination with regorafenib on colorectal cancer cell lines. Color Cancer. 7(2):CRC03.
   Web of Science ®Google Scholar
• Tatlidil D, Ucuncu M, Akdogan Y. 2015. Physiological concentrations of albumin favor drug binding. Phys Chem Chem Phys. 17(35):22678–22685.
   PubMed Web of Science ®Google Scholar
• Tayyab S, Feroz SR. 2021. Serum albumin: clinical significance of drug binding and development as drug delivery vehicle. Adv Protein Chem Struct Biol. 123:193–218.
   PubMed Web of Science ®Google Scholar
• Tesseromatis C, Alevizou A. 2008. The role of the protein-binding on the mode of drug action as well the interactions with other drugs. Eur J Drug Metabol Pharmacokinet. 33(4):225–230.
   PubMed Web of Science ®Google Scholar
• Tian H, Xu Y, Wang J, Tian W, Sun J, Zhang T, Zhou Q, Shao C. 2018. Effects of plasma albumin on the pharmacokinetics of esomeprazole in ICU patients. Biomed Res Int. 2018:1–6.
   Web of Science ®Google Scholar
• Toutain PL, Bousquet-Mélou A. 2004. Volumes of distribution. J Vet Pharmacol Ther. 27(6):441–453.
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. 2011. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 50:99–110.
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J. 2010. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother. 65(8):1771–1778.
   PubMed Web of Science ®Google Scholar
• Van Der Jeught K, Xu HC, Li YJ, Lu X Bin, Ji G. 2018. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 24(34):3834–3848.
   PubMed Web of Science ®Google Scholar
• Varnamkhasti BS, Jafari S, Taghavi F, Alaei L, Izadi Z, Lotfabadi A, Dehghanian M, Jaymand M, Derakhshankhah H, Saboury AA, et al. 2020. Cell-Penetrating peptides: as a promising theranostics strategy to circumvent the blood-brain barrier for CNS diseases. Curr Drug Deliv. 17(5):375–386.
   PubMed Web of Science ®Google Scholar
• Vincent JL. 2009. Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol. 23(2):183–191.
   PubMedGoogle Scholar
• Vincent J-L, Dubois M-J, Navickis RJ, Wilkes MM. 2003. Hypoalbuminemia in acute illness: is there a rationale for intervention? Ann Surg. 237(3):319–334.
   PubMed Web of Science ®Google Scholar
• Vuignier K, Schappler J, Veuthey JL, Carrupt PA, Martel S. 2010. Drug-protein binding: a critical review of analytical tools. Anal Bioanal Chem. 398(1):53–66.
   PubMed Web of Science ®Google Scholar
• Wanat K. 2020. Biological barriers, and the influence of protein binding on the passage of drugs across them. Mol Biol Rep. 47(4):3221–3231.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu XQ, Hou JS, Wang JN, Huang HZ. 2016. Molecular mechanisms of chemoresistance in oral cancer. Chinese J Dent Res. 19:25–33.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu S, Zhang Y, He J, Coy DH, Sun L. 2020. Human serum albumin (HSA) and its applications as a drug delivery vehicle. Health Sci J. 14:2.
   Google Scholar
• Wang X, Zhang H, Chen X. 2019. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2:141–160.
   PubMedGoogle Scholar
• Wunder A, Müller-Ladner U, Stelzer EHK, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C, et al. 2003. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol. 170(9):4793–4801.
   PubMed Web of Science ®Google Scholar
• Zahreddine H, Borden KLB. 2013. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 4:28.
   PubMed Web of Science ®Google Scholar
• Zhao P, Wang Y, Wu A, Rao Y, Huang Y. 2018. Roles of albumin‐binding proteins in cancer progression and biomimetic targeted drug delivery. ChemBioChem. 19(17):1796–1805.
   PubMed Web of Science ®Google Scholar
• Zheng HC. 2017. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 8(35):59950–59964.
   PubMedGoogle Scholar
• Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. 2007. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil Trans R Soc B. 362(1482):959–971.
   PubMed Web of Science ®Google Scholar
• Zhou P, Zhang R, Wang Y, Xu D, Zhang L, Qin J, Su G, Feng Y, Chen H, You S, et al. 2017. Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)- mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. Oncotarget. 8(67):111144–111160.
   PubMedGoogle Scholar
• Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H. 1997. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci. 94(8):3978–3983.
   PubMed Web of Science ®Google Scholar
• Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. 2016. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 10:1885–1895.
   PubMed Web of Science ®Google Scholar
• Zorzi A, Linciano S, Angelini A. 2019. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Med Chem Commun. 10(7):1068–1081.
   Web of Science ®Google Scholar